All Industries

DPH BIOLOGICALS BUILDS ON RESEARCH AND DEVELOPMENT COMMITMENT TO QUANTIFY FULL POTENTIAL OF BIOLOGICALS

DPH Biologicals

To instill confidence and foster innovation in the agricultural biologicals sector, DPH Biologicals announced the expansion of its science-first, data-verified approach with a multi-year effort to quantify the comprehensive value potential of biologicals. “DPH Bio has been committed to science that yields results from day one. Based on multi-year field research and through collaborations with our partners, we aim to provide customers a deeper understanding of the distinct value potential unlocked by biologicals,” said Mick Messman, President and CEO of DPH Bio, speaking at the 2024 Commodity Classic agricultural trade show in Houston that annually convenes thousands of growers. “Historically, return-on-investment has been measured by the cost to increase yield. However, our customers see the long-term value that biologicals deliver, such as improved soil health, water use efficiency, disease control, and plantability.” A review of 107 corn trials conducted over three years using TerraTrove SP-1 Classic revealed increased fertilizer efficiency in addition to average yield increase of 2.5 bushels per acre. “Although yield is an important metric, we believe it’s critical for growers to be able to measure the holistic value of biologicals in the field and across their entire business,” said Messman. “As we expand our portfolio and industry partnerships, we are pioneering the concept of ‘BioAgonomics’ to capture and maximize the full value proposition of biological solutions. As we further analyze the data, we are seeing some interesting trends based on management practices and soil conditions.” For example, in a multi-year study, SP-1 Classic averaged 6.5 more bushels per acre in high-yield, 220-bushel per acre corn in the Midwest. DPH Biologicals Introduces BioAgonomics™ to Redefine On-Farm Value Defined by DPH Bio as the branch of knowledge in agriculture focused on the connection between agronomic practices in crop production and the transfer and consumption of value uniquely unlocked by biologicals, BioAgonomics™ uses biologicals to create sustainable profitability and ingenuity across the supply chain, delivering the highest value in the field and for channel partners, including growers, ag retailers and advisors, product manufacturers and food companies. For instance, TerraTrove™ Residuce Complete delivers more than increased yield and fertilizer savings. As a comprehensive biodigester, Residuce accelerates the breakdown of crop residue, like corn stover and tough organic matter. A Michigan State University study revealed that corn stover contains 100 pounds of nitrogen (N), 50 pounds of phosphorus (P), and 210 pounds of potassium (K) an acre on a 200-bushell crop. In a recent field trial, Residuce delivered 19.7% degradation after a fall application. By leveraging these findings, Residuce can be calculated to provide 19.7 pounds of N, 9.85 pounds of P and 41.37 pounds of K, or more than $45 per acre in fertilizer savings. Furthermore, additional value can be quantified by accounting for factors, such as more uniform seedling emergence, reduced farm equipment wear and tear, reduction of the disease host, and improved plant standability, as well as the retention and conversion of carbon within the soil. Through collaborations with trusted advisors, including prominent researchers at University of Illinois, DPH Bio will continue to collect and evaluate data to calculate biologicals’ comprehensive value to growers in aspects beyond yield. “With advanced scientific research and on-farm trials, results can easily be seen in the field, but we aspire for more,” said Messman. “The pivotal convergence of biologicals, agronomy and economics holds the key for a triple bottom-line impact by improving crop production, land stewardship and rural livelihoods. Looking ahead, and in collaboration with our partners, our mission is to give growers an even clearer, comprehensive view of their investment in biologicals.” For more information, growers participating in Commodity Classic are invited to visit DPH Bio at Booth 6945 on the third floor of the George Brown Convention Center. In addition, the company plans a series of workshops, including a CropLife webinar on March 5th. # # # About DPH Biologicals DPH Biologicals, LLC attracts, develops and scales technologies improving broad market access and simplifying the grower experience with biologicals. Based on investments in scientific research, field testing, partner relationships and product development, and leadership-owned since 2024, DPH Bio yields success through science and relationships, standing at the leading edge of clarity, trust and proven, profitable solutions for agricultural biologicals. For more information, visit www.dphbio.com. Contact Details AgTech PR for DPH Biologicals Sara Winters sara@agtechpr.com Company Website http://www.dphbio.com

February 29, 2024 08:00 AM Central Standard Time

Image

Silence Laboratories Raises $4.1M Funding to Enable Privacy Preserving Collaborative Computing

Silence Laboratories

In the modern age, large companies are wrestling to leverage their customers’ data to provide ever-better AI-enhanced experiences but a key barrier to leveraging this opportunity is mounting public concern around data privacy, as ever-greater data processing poses risks of data leaks by hackers and malicious insiders. Silence Laboratories is on a mission to create infrastructure to enable complex data collaborations between enterprises and entities, without any sensitive information being exposed to the other engaging parties. Silence Laboratories today announces it has raised an additional $4.1 million funding round led by Pi Ventures and Kira Studio, along with several prominent angel investors. Leveraging modern cryptography, the company already has one of the fastest distributed signature (authorization) libraries in production ( Silent Shard ), which has been audited by some of the best security auditing companies like Trail of Bits. These libraries have led to the establishment of strong partnerships with leading digital asset infrastructure and protocol companies like BitGo, MetaMask, EigenLayer, Biconomy, and EasyCrypto. Products on offer by the company include Silent Shard which allows enterprises and users to limit the risk of exposing sensitive private keys and allows advanced authorisation rules to be put in place. Additionally, the newly launched Silent Compute product allows different organisations to collaborate on processing information without needing to expose their secrets and data to third parties and enrich insights while maintaining compliance and trust. Both the products uses multi-party computation (MPC) as its core cryptographic primitives. Commenting on the announcement, Silence Laboratories CEO and founder Dr. Jay Prakash said: “In today's digital ecosystem, trust, and privacy are not merely options but imperatives for sustainable growth. With this new injection of funds, Silence Laboratories is poised to redefine privacy by enabling businesses to fully embrace the power of AI while rigorously protecting their most vital asset – customer trust. Our privacy-enhancing technologies assure that collaboration and innovation can flourish in an environment where the confidentiality and integrity of data are uncompromised.” With the market for privacy-enhancing technologies (PETs) growing globally at a compound annual growth rate of 26.6%, there is growing demand for Silence Laboratories offering to provide mathematical guarantees for techno-legal expectations. This would allow companies to work together on processing data, without needing to share data with the other party - allowing more sectors to benefit from new technology, with less risk. Shubham Sandeep, Managing Director Pi Ventures, commented: "Secure data collaboration to enable privacy preserving compute is an ever growing problem especially in highly regulated domains such as finance and healthcare. This requires solutions based on zero trust cryptographic guarantees instead of relying on third party data vendors who are prone to security breaches. The MPC infrastructure developed by the world class team at Silence Laboratories is the fastest in the world, easily configurable, application agnostic and provides full control to the user. We are excited to double down on our investment as we have seen the fantastic progress of the company over the last 18 months." The funding will be used to scale the company’s tech & business teams and enrich the company’s robust R&D pipeline. Founded in 2021 by Dr. Jay Prakash (CEO), Dr. Andrei Bytes (CTO) and Dr. Tony Quek; the firm has also recently been expanding its global leadership team across cryptography, infrastructure business and engineering. “The Silence team is an amazing team with deep cryptography expertise and is working on a set of groundbreaking products in privacy and authentication infrastructure and I am really excited to support their journey. Privacy-preserving infrastructure combined with blockchain and fintech rails is going to be huge!” shared Anurag Arjun, from Kira Studio and Ex Co-founder of Polygon. About Silence Laboratories Started in 2021 by Dr. Jay Prakash (CEO) and Dr. Andrei Bytes (CTO), Silence Laboratories is a privacy tech company that enables enterprises to adopt privacy-enhancing technologies through a unique fusion of cryptography and security engineering. Their mission is to enable a global privacy-compliant collaboration infrastructure that would enable enterprises to collaborate, and exchange inferences while removing all single points of failure. The company has been founded by a strong technical and business team including PhDs and researchers with previous affiliations at the Massachusetts Institute of Technology (MIT), USA; Singapore University of Technology & Design (SUTD) & National University of Singapore (NUS); University of Illinois Urbana-Champaign (UIUC), globally top-ranked Capture The Flag (CTF) teams, and leading tech companies. Learn more about their work: https://silencelaboratories.com Contact Details Silence Laboratories Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://www.silencelaboratories.com/

February 29, 2024 09:00 AM Eastern Standard Time

Image

Responsible Gambling Affiliate Association Announces Appointment of George Rover as Executive Director

Responsible Gambling Affiliate Association

Responsible Gambling Affiliate Association, the industry trade coalition that advocates for reasonable regulation, responsible advertising, and consumer protection has appointed George Rover as its first Executive Director to lead the organization. Comprising of six major players in the US online gambling affiliate sector, the Association includes Better Collective, Catena Media, FairPlay Sports Media, Gambling.com Group, Spotlight Sports Group, and XLMedia PLC. As Executive Director, Rover will be responsible for executing the RGAA’s long-term mission to safeguard responsible gambling marketing and advertising practices. His duties as Executive Director will be pivotal in shaping the future of responsible affiliate practices, advocating the needs and interests of the Group’s members, promoting sensible regulation, fostering collaboration with industry stakeholders, and advocating for the highest standards of integrity. "In the spirit of collaboration - whether it be with state regulators, politicians, legislators or online gambling operators, I look forward to working with key stakeholders and will champion the critical role affiliate companies play in the regulated online gambling ecosystem,” said Rover. “The formation of the RGAA will provide this essential segment of the industry with an important and constructive voice to promote responsible gambling, prioritizing the best interests of consumers through a unified set of high standards and guidelines to achieve long-term success." Prior to joining the RGAA, Rover held numerous senior positions with the New Jersey Department of Law and Public Safety, Office of the Attorney General and the New Jersey Division of Gaming Enforcement (NJDGE). At the NJDGE, Rover oversaw the agency’s Service Industry Licensing, Casino Prosecutions, Internet Gaming and Technical Services Bureaus. During his tenure, he directed the successful launch of Internet Gaming in New Jersey and supervised some of the NJDGE’s most complex licensing and organized crime investigations and prosecutions. After his retirement from government service, Rover also worked closely with the industry’s leading gaming companies to form the Sports Wagering Integrity Monitoring Association (SWIMA), a national non-profit organization with the mission to detect and discourage fraud and other illegal activity related to betting on sporting events. In addition to his role with the RGAA, Rover will continue to support companies in the gaming industry through his strategic gaming advisory company, Princeton Global Strategies. "We are thrilled to welcome George Rover to the RGAA family,” said Katie McCord, Chair of the Responsible Gambling Affiliate Association. “His unparalleled expertise, spanning decades in casino and sports betting law, will undoubtedly elevate our organization. George's substantial contributions to the industry, including spearheading initiatives like SWIMA, showcase his commitment to integrity and innovation." Rover will participate in a fireside chat at the Next.io Online Gambling and Sports Betting Summit in New York on March 4 to discuss the dangers of the offshore and unregulated market which continues to target consumers in the US who still lack education regarding legitimate operators. Learn more about the RGAA here: www.rgaa.org Responsible Gambling Affiliate Association (RGAA) is an independent trade association comprised of companies that engage in gambling, gaming, or sports betting marketing and advertising. Its mission is to champion responsible gambling marketing and advertising practices, advocate for sensible regulation, and protect consumer best interest while effectively serving the market. RGAA was founded in 2023 by Better Collective, Catena Media, FairPlay Sports Media, Gambling.com Group, Spotlight Sports Group, and XLMedia plc. Contact Details Digital Sport by Hot Paper Lantern Jackson Gaskins Jgaskins@hotpaperlantern.com Company Website https://rgaa.org

February 29, 2024 09:00 AM Eastern Standard Time

Zodiac Gold Announces Positive Initial Phase II Drill Results, Including 9.14 m at 4.20 g/t Au and 10.20 m at 1.23 g/t Au, Including 2.81 m at 2.95 g/t Au

Zodiac Gold Inc.

Toronto, ON – TheNewswire - February 28, 2024 - Zodiac Gold Inc. (“ Zodiac Gold ” or the “ Company ”) (TSXV: ZAU) i s pleased to report positive initial results from its Phase II Drill Program consisting of assay results from three recently completed diamond drill holes at the Company’s Arthington Target. The Arthington Target is positioned within an 18.5 km long district-scale mineralization trend and is one of the five high-priority, multi-kilometer drill - ready targets situated within the 2,316 km 2 Todi gold project (the “ Todi Project ”) l ocated in the Republic of Liberia, West Africa. In 2022, the Company completed a 3,465m Phase I Drill Program targeting an 800m strike at Arthington which intersected multiple intervals of gold mineralization in 20 of 22 holes including the highest-grade interval drilled to date: AD007, which intersected 7.5 g/t over 9.65m from 87.35m. Phase II Drill Program Initial Results The Company is currently conducting a 2, 000m Phase II Drill Program at Arthington targeting Garang Base, Red Hill, & Deep Mine. Today, the Company is pleased to report assay results from an initial three drill holes (ADD23, ADD24, & ADD25) which successfully intercepted multiple intervals of shear zone-hosted gold mineralization enlarging the known mineralization footprint from Red Hill to 400 meters southeast towards the Garang Base target (See Figure-1). Click Image To View Full Size Figure-1: Map showing significant intercepts at Red Hill and Garang Base zones of the Arthington Target These three initial drill holes (see below) revealed shear-hosted gold mineralization with intercepts cutting through multiple shallowly dipping mineralized zones associated with shears across a 300m wide corridor of the Arthington Shear Zone. This extensive gold bearing zone spans at least 1, 000m along strike and reaches vertical depths of 140m, illustrating a substantial orogenic gold footprint along the prominent Todi Shear Zone system. Notable mineralized shear structures include intervals in hole ADD24, with 25. 9m averaging 2.10 g/t Au, including 9. 14m at 4.20 g/t Au, and 10. 20m at 1.23 g/t Au, including 2. 81m at 2.95 g/t Au. The continuity of mineralization is highlighted by three distinct intervals in hole ADD23, ADD24 and ADD25 which underscore the significant potential of the Arthington Target and the Todi Project overall. Management Commentary David Kol, President & CEO of Zodiac Gold, stated “These initial Phase II results are very positive and drilling to date has only scratched the surface of our vast land package. Arthington has delivered some significant gold intercepts thus far and with each drill hole, its potential continues to grow. We look forward to additional drill results from our ongoing Phase II program to further enhance the strike length and width at Arthington.” Highlights from the initial Phase II drill program include: Table 1: Significant Intercepts at the Arthington Target Table 2: Collar Information for the Reported Holes QA/QC Protocols and Sampling Procedures The drilling program at Arthington was conducted by a Fordia Eider 2000 diamond drill rig with HQ and NQ diameter core. Core recoveries were excellent throughout the program approaching 100%. Drill core was transported from the drill site to the Company’s exploration camp facility. After geological logging, the core was cut along the long axis by a diamond saw, with half being sampled and half retained. Core sampling was undertaken by Zodiac Gold’s Liberian exploration team, supervised by senior staff members of the Company. All core samples met the standards for adequate chain of custody without the opportunity for third party access from the field to the preparation laboratory in Monrovia, Liberia, and then onward to the SGS analytical laboratory in Ghana. Sample preparation was performed by Liberia Geochemical Services Inc. in Monrovia. The entire core sample was dried and then crushed to 70% passing -2 millimeters and a representative split was taken by riffle splitting. The 1, 000g split was then pulverized up to 85% passing -75 micron and the required pulp mass of ~ 200g was bagged and labelled for analysis; with the remainder being stored. Analysis was performed by SGS at their laboratory in Ghana by fire assay with atomic absorption finish with a 50g charge. In addition to the laboratory's quality control program, a rigorous quality assurance and quality control program was implemented by the Company involving the insertion of blanks, standards and duplicates to ensure reliable assay results. Laboratory standards and QA-QC are monitored by the Company. About Zodiac Gold Zodiac Gold, Inc. (TSX.V:ZAU) is a West-African gold exploration company focused on its flagship Todi Project situated in Liberia—an underexplored, politically stable, mining-friendly jurisdiction hosting several large-scale gold deposits. Strategically positioned along the fertile Todi Shear Zone, Zodiac Gold is developing a district-scale gold opportunity covering a vast 2,316 km 2 land package. The project has undergone de-risking, showcasing proven gold occurrences at both surface and depth, with five drill-ready targets and high-grade gold intercepts. Qualified Person Efdal Olcer, Vice President of Exploration at Zodiac Gold, is a member of the Society of Economic Geologists, Geological Society of London, Australian Institute of Geoscientists, the Society of Geology Applied to Mineral Deposits, and the Turkish Association of Economics Geologists and a Qualified Person as defined by NI 43-101. He has reviewed and approved the technical and scientific information provided in this release. For further information, please visit the Zodiac-Gold website at www.zodiac-gold.com or contact: David Kol President & CEO info@zodiac-gold.com Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward Looking Information This news release includes certain “forward-looking statements” within the meaning of Canadian securities legislation. Forward-looking statements include predictions, projections, and forecasts and are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “forecast”, “expect”, “potential”, “project”, “target”, “schedule”, “budget” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions and includes the negatives thereof. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding the Company’s planned exploration programs and drill programs and potential significance of results are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are based on a number of material factors and assumptions. Important factors that could cause actual results to differ materially from Company’s expectations include actual exploration results, changes in project parameters as plans continue to be refined, results of future resource estimates, future metal prices, availability of capital, and financing on acceptable terms, general economic, market or business conditions, uninsured risks, regulatory changes, defects in title, availability of personnel, materials, and equipment on a timely basis, accidents or equipment breakdowns, delays in receiving government approvals, unanticipated environmental impacts on operations and costs to remedy same, and other exploration or other risks detailed herein and from time to time in the filings made by the Company with securities regulators. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ from those described in forward-looking statements, there may be other factors that cause such actions, events, or results to differ materially from those anticipated. There can be no assurance that forward-looking statements will prove to be accurate, and accordingly readers are cautioned not to place undue reliance on forward-looking statements.

February 29, 2024 08:30 AM Eastern Standard Time

Image

Altius Minerals’ (OTCQX: ATUSF) Development Stage Royalty Could Become Its Largest As Global Steel Industry Transitions Away From Coal

Benzinga

By Faith Ashmore, Benzinga Steelmaking is one of the oldest industries in the world. Currently, steelmaking is divided into two different processes: the use of electric arc furnaces and the use of blast oxygen furnaces. Blast oxygen furnaces melt iron ore with coal whereas electric arc furnaces use electricity and scrap steel to melt iron ore. As the world works on decreasing carbon emissions, blast oxygen furnaces are coming under scrutiny due to their high production of CO2. Electric arc furnaces are more environmentally friendly because of the decreased reliance on coal. Today, 70% of steel made in the U.S. comes from electric arc furnaces, and as other economies follow suit, it will be important that industries have the infrastructure in place to convert to a more environmentally friendly process. One of the big questions surrounding this issue is whether there is enough scrap metal available for the process to be sustainable. Luckily, DR-grade (direct reduced) iron is a suitable substitute for scrap metal and in some cases could even be 100% of the input when using electric arc furnaces. Altius Minerals (OTCQX: ATUSF) (TSX: ALS) holds a strategic royalty on the Kami Project. Altius Minerals is a 27-year-old mining royalty company that has a royalty portfolio in copper, other battery metals, potash, renewable energy and high-grade/low-impurity iron ore. Exposure to potash and renewable energy has already positively situated Altius Minerals in some of the key markets in the 21st century, but its iron ore royalty may also be advantageous to the greening of the steel industry. In 2021, Champion Iron (OTCMKTS: CIAFF) acquired the Kami Project in Newfoundland and Labrador, near the Quebec eastern border. Altius reports that the Kami Project stands out as a promising DR-grade iron ore project situated in a strategic location in the Labrador Trough geological belt. Positioned just a short distance from the company's operating Bloom Lake mine, the project benefits from existing infrastructure and a high-purity iron resource that has been significantly de-risked by its previous owners. Altius Minerals shares that the company has a 3% gross sales revenue royalty in the Kami Project, or a 2.6% gross sales revenue royalty after deducting the amount that goes to the province. By the company’s estimates, the gross sales revenue might look something like this: if the price was $154/tonne (base price in the Project Study) and volumes sold were consistent with the Project Study, royalty revenue to Altius would be roughly $30 - $35 million Canadian per year. Altius Minerals is confident that if projects come to fruition, investment in the Kami Project will become Altius’s largest royalty. The global iron and steel market size is astronomical; in 2022 it was valued at $1.676 trillion, and it is expected to grow at a CAGR of 3.8% from 2023 to 2030. As more and more industry leaders transition to greener steel manufacturing and use electric arc furnaces, companies like Altius Minerals could be well-positioned to profit. Featured photo by James Baltz on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 29, 2024 08:30 AM Eastern Standard Time

Image

For The First Time The US Is Set To Hit 2 Million New Cancer Cases: Theriva Biologics Presents Novel Solutions To The Deadliest Cancers

Benzinga

By Faith Ashmore, Benzinga A recent cancer study showed that the incidence rates of early-onset cancer “increased substantially” from 2010 to 2019. Breast cancer had the highest number of incident cases, and gastrointestinal cancers had the fastest-growing incidence rates among all early-onset cancers. The National Cancer Institute reports that colorectal cancer has become the leading cause of cancer-related deaths for Americans aged 20 to 59 years old. Doctors are expecting that in 2024, there will be more than 2 million new cases of cancer; this would be the first year the U.S. would cross that threshold, marking almost 5,500 cancer diagnoses a day. The increasing cancer incidence, especially among young people, is a big cause for concern in the medical community. Specifically, there is an increase in pancreatic cancer, which is expected to become the second-highest cause of cancer-associated deaths in 2030 in the U.S. Fortunately, fatality rates from cancer have steadily been on the decline for the past 30 years. This is largely due to better detection systems and advancements in treatment. Theriva Biologics (AMEX: TOVX) is one of the biotech companies that is helping push the envelope in cancer treatment. The company specializes in developing oncolytic viruses that are unique and highly differentiated. These viruses have been optimized for systemic administration and are designed to treat various types of cancer and make other cancer therapies more effective. They are optimized to be administered in combination with chemotherapy and immunotherapies, increasing access to the tumor and exposing the tumor to the immune system. The company’s lead drug candidate is VCN-01, which is a uniquely engineered human adenovirus 5. VCN-01 also expresses a protein named hyaluronidase that degrades the dense matrix surrounding human tumors, and this helps the action of chemotherapy and immunotherapies. The phase 1 clinical trials of VCN-01 have shown promising results for the treatment of several additional indications such as pancreatic cancer, retinoblastoma, head and neck squamous cell carcinoma (HNSCC) and colorectal cancer (CRC) in combination with chemotherapy and immunotherapies. The company's innovative Albumin Shield™ platform and oncolytic virus discovery engine have enabled the development of a distinct product pipeline that holds promise in the fight against cancer. Currently, the company is conducting a phase 2b clinical trial of its VCN-01 in combination with standard-of-care chemotherapy for first-line metastatic pancreatic cancer. Theriva Biologics is on track to complete enrollment into the VIRAGE Study by the first half of 2024. In the first quarter of 2024, a Drug Monitoring Committee (DMC) conducted a thorough safety review of VCN-01, ensuring that the drug meets the necessary criteria for continued development. By the second half of 2024, Theriva Biologics aims to perform an interim analysis of the data obtained from the VIRAGE Study. Theriva Biologics And Its Potential Markets By The Numbers The pancreatic cancer market’s size was estimated at $2.2 billion in 2022, and it's expected to grow at a CAGR of 13.6% between 2023 and 2032, reaching approximately $7.91 billion by 2032. Theriva Biologics seems well-positioned to excel in this space with its innovative VCN-01 drug candidate, with the potential to also serve other multi-billion dollar markets – such as head and neck cancer drugs, set to surpass $2.99 billion by 2030. Theriva Biologics reported $31.6 million in cash and short-term investment for Q3 2023. The company also increased research expenses to $4 million from $2.6 million a year ago while decreasing general and administrative expenses by 91% y-o-y. The company narrowed its net loss for the quarter from $4.49 million in Q3 2022 to $3.3 million in Q3 2023, and the basic loss per share for the quarter was $0.19 compared to $0.3 a year ago. Theriva Biologics currently has a market capitalization of about $8 million. The clinical-stage company’s innovative drug research might present a novel solution to extend the lives of those suffering from the deadliest of cancers, providing patients with new hope and improved outcomes. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 29, 2024 08:25 AM Eastern Standard Time

Image

OLB Group is Making Omnicommerce and Wireless Plans Accessible to the Underbanked and Revolutionizing Payments for Businesses

Benzinga

By Faith Ashmore, Benzinga Omnicommerce is an integrated "all-channel" retail approach that provides consistent, seamless and personalized customer experiences, ultimately leading to secure and frictionless payments. It encompasses meeting customers where they are, whether through physical stores, online platforms, social media or other digital spaces. By adopting an omnichannel strategy, businesses can create a unified brand presence and deliver a smooth consumer experience across multiple channels. As technology continues to advance and consumer expectations evolve, the omnicommerce industry will continue to grow and play a significant role in shaping the future of the retail industry. In 2022, the global market size of retail omnichannel commerce platforms was $8.1 billion, and is projected to grow at a CAGR of 16.6% from 2022-2030. Businesses today are investing more in developing omnicommerce solutions, such as mobile websites, apps, personalized email marketing and social media integration. However, not all businesses have the technology to adopt this approach and have to look to third-party technology companies for help. That’s where companies like OLB Group (NASDAQ: OLB) come into play to make omnicommerce more accessible. OLB offers a comprehensive suite of products and services, catering to the needs of small and medium-sized enterprises (SMEs) as well as larger organizations. OLB's flagship product, OmniSoft, is a cloud-based e-commerce platform that enables businesses to easily establish an online presence, manage and track their sales and accept payments securely. In June 2023, OLB acquired a controlling interest in black011.com, which encompasses Black Wireless and Mango Mobile, and is beginning to contribute to revenues. These strategic moves enabled the company to offer one Point of Sales (POS) system to customers so they can purchase products and seamlessly reload mobile phone minutes.. OLB is in the process of rebranding these platforms and integrating them into the OLB Payment Platform and ECO Payment system. Ultimately, these acquisitions enable OLB to focus on the rapidly growing underbanked communities. As of 2022, a market study revealed that approximately 13% of American adults were underbanked, a new market that OLB has identified as underserved. Increased accessibility can dramatically help these communities and provide bodegas and convenience stores with a new service to their customers. In November, the company reported a wider-than-expected quarterly loss, but an often overlooked accounting technicality is that the loss was largely due to non-cash depreciation “expense”. However, to underscore the confidence in the company’s future, Chairman and CEO Ronny Yakov acquired a total of 784,212 shares and Vice President Patrick Smith purchased a total of 392,106 shares at an average price of $0.77. OLB also provides various payment processing solutions, such as point-of-sale systems, mobile payment applications and virtual wallets – allowing businesses to accept payments from customers through multiple channels. To date, the company has worked with 10,500 merchants worldwide and secured over 28.5 million transactions annually in over 130 different industries. OLB prides itself on being a comprehensive single solution with over 15 years of experience. The company runs on the SaaS model with pay-as-you-go options, making its platform more accessible to businesses of all sizes. With a modest market capitalization of around $13 million and an annual revenue run rate of over $30 million (one of the lowest Price to Sales ratios of 0.3 times sales vs. a peer average of 1 x sales), OLB Group may represent an opportunity for investors interested in participating in the broadening out of the payments industry to include more of the underbanked. The emergence of omnicommerce reflects the next evolution in e-commerce for both businesses and customers alike and the growing recognition of payments as a cornerstone in every customer journey. With the convenience and accessibility of online shopping, customers now expect a seamless and personalized shopping experience across various touchpoints. With a commitment to empowering businesses with efficient and secure payment solutions, OLB is establishing itself as a trusted provider in the payments industry. Featured photo by Mark König on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 29, 2024 08:20 AM Eastern Standard Time

Image

MAIA Biotech Completes Enrollment For Phase 2 Trial Of Its Candidate THIO To Fight Non-Small Cell Lung Cancer

Benzinga

By Meg Flippin, Benzinga MAIA Biotechnology Inc. (AMEX: MAIA), the clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, completed enrollment for its phase 2 trial for THIO, its lead therapy to fight advanced non-small cell lung cancer or NSCLC. NSCLC is a disease in which cancer cells form in the tissues of the lung. It’s the most common form of lung cancer in the U.S., accounting for 81% of lung cancer diagnoses. The five-year survival rate for this type of cancer is 28%. THIO targets and compromises the function of telomeres, which play a key role in helping cancer cells live and spread. Telomeres are made from DNA sequences and proteins and sit at the end of chromosomes, capping and protecting them in the cell division progress. Telomeres can be regenerated with the support of telomerase, an enzyme present in the early stages of growth and development in humans and in very few cells of adults. Telomerase is present in nearly all cancers and is expressed in 80% of NSCLC tumors. Evaluating The Effectiveness THIO is recognized by telomerase, leading to the uncapping of telomeres and thus resulting in rapid tumor cell death. THIO induces telomerase-dependent telomeric DNA modification, DNA damage responses and selective cancer cell death. The phase 2 THIO-101 go-to-market clinical trial is designed to evaluate THIO sequenced with the immune checkpoint inhibitor cemiplimab (Libtayo®) in patients with NSCLC. In preclinical models in vivo, MAIA demonstrated that low doses of THIO followed by anti-PD-L1 or anti-PD1 therapy completely eliminated advanced tumors and produced cancer cell-specific memory to activate the immune system against the cancer cells after extended periods with no need for additional treatment. Enrollment Reached Ahead Of Schedule Earlier in February, the trial reached its enrollment target of 41 patients for the 180 mg dose. Initially, the trial was designed to test three dose levels but following the selection of 180 mg/cycle as the optimal dose in December all patients were enrolled at that dose level and trial enrollment was completed ahead of schedule, the company said in a press release. “Enrollment in our Phase 2 THIO-101 trial has been strong from the start. With excellent results across all doses and our selection of the optimal dose in December 2023, we enrolled the necessary number of patients in the Simon 2-stage design to achieve our trial endpoints earlier than expected,” said Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer when announcing the enrollment results. “THIO-101 preliminary data has demonstrated unprecedented rates of disease control and response to date, and we look forward to the long-term efficacy results as we continue to monitor the enrolled patients in the upcoming months.” THIO Well Tolerated The main objectives of the trial are to evaluate the safety, tolerability and preliminary clinical efficacy of THIO in patients with advanced NSCLC who have experienced disease progression or relapse after initial treatments with an immune CPI alone or in combination with chemotherapy. THIO is currently being developed as a second or later line of treatment for NSCLC patients who have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors. MAIA Biotechnology said treatment with THIO followed by cemiplimab (Libtayo®) followed by THIO has been generally well tolerated to date in a heavily pre-treated population. “As the only direct telomere targeting agent currently undergoing clinical development in the field of cancer, we believe THIO holds a time-to-market advantage and strong potential to become a new standard of care for NSCLC,” said Vitoc. While THIO is currently being tested for NSCLC, telomerase is present in 85% to 95% of human cancers and contributes to the proliferation and reproductive immortality of cancer cells. As a result, the company is studying THIO in models of several tumor types with active telomerase, including rate indications in liver, colorectal and brain cancers. That could result in further use cases for MAIA’s lead treatment. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 29, 2024 08:15 AM Eastern Standard Time

Image

TeamBuilder's Innovative Staff Scheduling Solution Recognized in KLAS Insights Report

TeamBuilder

TeamBuilder, an innovative workforce management solution, has been featured in the latest insights report by KLAS, a renowned healthcare research firm. The report, titled "Emerging Insights Case Study on Workforce Management and Predictive Staff Scheduling through a Digital Platform," highlights TeamBuilder's pioneering approach to staff scheduling and its positive impact on healthcare organizations. Staff scheduling in healthcare has a unique set of challenges that can be exacerbated by provider volume and manual processes for clinical workflow management. These challenges can lead to problematic patient care and poor provider and staff experiences. The TeamBuilder solution, built specifically for ambulatory care, is intended to alleviate organizational pain points around staff scheduling by assessing the needs of day-to-day operations and offering predictive staff scheduling. Key findings from the case study include: Improved Operational Efficiency: TeamBuilder's predictive staff scheduling reduces administrative burdens and streamlines day-to-day operations, allowing healthcare organizations to focus on delivering quality patient care. Enhanced Staff Experience: Users of TeamBuilder's platform reported positive experiences, citing the ease of use, real-time notifications, and centralized communication features as key strengths. Positive Organizational Outcomes: TeamBuilder's digital schedule and recommendation engine drive positive outcomes, including workforce management optimization, reduced staffing costs, and improved visibility into staffing utilization across multiple sites. "What's been done traditionally around using staffing ratios often leads to chronic overstaffing and understaffing because they don't account for nuances like shifting patient volume, provider workflow and sites that answer phones," said David Howard, CEO and Founder of TeamBuilder. "What we've been able to do with TeamBuilder is to use data science to consume all of the nuances of a clinic's operating model and provide managers with the optimal schedule each week. No more paper. No more guessing." To read the full report, visit TeamBuilder — News. About TeamBuilder: TeamBuilder is a predictive staff scheduling platform built specifically for ambulatory care. Contact Details TeamBuilder Media info@teambuilder.io Company Website https://teambuilder.io/

February 29, 2024 08:00 AM Eastern Standard Time

1 ... 377 378 379 380 381 ... 3754